x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
(State
or Other Jurisdiction of Incorporation or Organization)
|
75-3142681
(I.R.S.
Employer Identification No.)
|
811
Hansen Way, Palo Alto, California 94303
(Address
of Principal Executive Offices and Zip Code)
|
|
(650)
846-2900
(Registrant’s
telephone number, including area code)
|
|
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last
report)
|
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Assets
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 27,863 | $ | 28,670 | ||||
Restricted
cash
|
1,101 | 776 | ||||||
Accounts
receivable, net
|
41,882 | 47,348 | ||||||
Inventories
|
68,321 | 65,488 | ||||||
Deferred
tax assets
|
13,146 | 11,411 | ||||||
Prepaid
and other current assets
|
3,808 | 3,823 | ||||||
Total
current assets
|
156,121 | 157,516 | ||||||
Property,
plant, and equipment, net
|
60,346 | 62,487 | ||||||
Deferred
debt issue costs, net
|
4,321 | 4,994 | ||||||
Intangible
assets, net
|
77,024 | 78,534 | ||||||
Goodwill
|
162,293 | 162,611 | ||||||
Other
long-term assets
|
3,651 | 806 | ||||||
Total
assets
|
$ | 463,756 | $ | 466,948 | ||||
Liabilities
and stockholders’ equity
|
||||||||
Current
liabilities:
|
||||||||
Current
portion of long-term debt
|
$ | - | $ | 1,000 | ||||
Accounts
payable
|
21,065 | 21,109 | ||||||
Accrued
expenses
|
21,924 | 23,044 | ||||||
Product
warranty
|
3,981 | 4,159 | ||||||
Income
taxes payable
|
3,612 | 7,766 | ||||||
Advance
payments from customers
|
12,898 | 12,335 | ||||||
Total
current liabilities
|
63,480 | 69,413 | ||||||
Deferred
income taxes
|
26,508 | 27,321 | ||||||
Long-term
debt, less current portion
|
217,916 | 224,660 | ||||||
Other
long-term liabilities
|
1,897 | 1,689 | ||||||
Total
liabilities
|
309,801 | 323,083 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
equity
|
||||||||
Common
stock ($0.01 par value, 90,000 shares authorized; 16,723 and 16,538
shares issued; 16,517
and 16,332 shares outstanding)
|
167 | 165 | ||||||
Additional
paid-in capital
|
73,824 | 71,818 | ||||||
Accumulated
other comprehensive loss
|
(5,071 | ) | (1,809 | ) | ||||
Retained
earnings
|
87,835 | 76,491 | ||||||
Treasury
stock, at cost (206 shares)
|
(2,800 | ) | (2,800 | ) | ||||
Total
stockholders’ equity
|
153,955 | 143,865 | ||||||
Total
liabilities and stockholders' equity
|
$ | 463,756 | $ | 466,948 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
April 3,
2009
|
March 28,
2008
|
April 3,
2009
|
March 28,
2008
|
|||||||||||||
Sales
|
$ | 81,903 | $ | 94,804 | $ | 159,049 | $ | 180,714 | ||||||||
Cost
of sales
|
60,137 | 66,738 | 117,367 | 128,512 | ||||||||||||
Gross
profit
|
21,766 | 28,066 | 41,682 | 52,202 | ||||||||||||
Operating
costs and expenses:
|
||||||||||||||||
Research
and development
|
3,157 | 2,930 | 5,340 | 5,654 | ||||||||||||
Selling
and marketing
|
4,801 | 5,328 | 9,790 | 10,500 | ||||||||||||
General
and administrative
|
5,196 | 5,492 | 10,400 | 11,645 | ||||||||||||
Amortization
of acquisition-related intangible assets
|
691 | 781 | 1,385 | 1,562 | ||||||||||||
Net
loss on disposition of fixed assets
|
44 | 41 | 64 | 75 | ||||||||||||
Total
operating costs and expenses
|
13,889 | 14,572 | 26,979 | 29,436 | ||||||||||||
Operating
income
|
7,877 | 13,494 | 14,703 | 22,766 | ||||||||||||
Interest
expense, net
|
4,306 | 4,805 | 8,761 | 9,617 | ||||||||||||
(Gain)
loss on debt extinguishment
|
(197 | ) | 393 | (197 | ) | 393 | ||||||||||
Income
before income taxes
|
3,768 | 8,296 | 6,139 | 12,756 | ||||||||||||
Income
tax expense (benefit)
|
79 | 2,142 | (5,205 | ) | 4,092 | |||||||||||
Net
income
|
$ | 3,689 | $ | 6,154 | $ | 11,344 | $ | 8,664 | ||||||||
Other
comprehensive income, net of tax
|
||||||||||||||||
Net
unrealized gain (loss) on cash flow hedges and other comprehensive
income
|
617 | (2,001 | ) | (3,262 | ) | (3,202 | ) | |||||||||
Comprehensive
income
|
$ | 4,306 | $ | 4,153 | $ | 8,082 | $ | 5,462 | ||||||||
Earnings
per share - Basic
|
$ | 0.23 | $ | 0.38 | $ | 0.70 | $ | 0.53 | ||||||||
Earnings
per share - Diluted
|
$ | 0.21 | $ | 0.35 | $ | 0.65 | $ | 0.49 | ||||||||
Shares
used to compute earnings per share - Basic
|
16,317 | 16,387 | 16,293 | 16,379 | ||||||||||||
Shares
used to compute earnings per share - Diluted
|
17,319 | 17,656 | 17,353 | 17,744 |
Six Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Cash
flows from operating activities
|
||||||||
Net
cash provided by operating activities
|
$ | 7,865 | $ | 10,439 | ||||
Cash
flows from investing activities
|
||||||||
Capital
expenditures
|
(1,818 | ) | (2,558 | ) | ||||
Proceeds
from adjustment to acquisition purchase price
|
- | 1,615 | ||||||
Payment
of patent application fees
|
- | (147 | ) | |||||
Net
cash used in investing activities
|
(1,818 | ) | (1,090 | ) | ||||
Cash
flows from financing activities
|
||||||||
Repayments
of debt
|
(7,495 | ) | (10,000 | ) | ||||
Proceeds
from issuance of common stock to employees
|
605 | 418 | ||||||
Proceeds
from exercise of stock options
|
36 | - | ||||||
Net
cash used in financing activities
|
(6,854 | ) | (9,582 | ) | ||||
Net
decrease in cash and cash equivalents
|
(807 | ) | (233 | ) | ||||
Cash
and cash equivalents at beginning of period
|
28,670 | 20,474 | ||||||
Cash
and cash equivalents at end of period
|
$ | 27,863 | $ | 20,241 | ||||
Supplemental
cash flow disclosures
|
||||||||
Cash
paid for interest
|
$ | 8,323 | $ | 8,293 | ||||
Cash
paid for income taxes, net of refunds
|
$ | 2,270 | $ | 8,722 |
1.
|
The
Company and a Summary of its Significant Accounting
Policies
|
2.
|
Recently
Issued Accounting Standards
|
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Accounts
receivable
|
$ | 41,994 | $ | 47,437 | ||||
Less:
Allowance for doubtful accounts
|
(112 | ) | (89 | ) | ||||
Accounts
receivable, net
|
$ | 41,882 | $ | 47,348 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Raw
material and parts
|
$ | 39,401 | $ | 40,187 | ||||
Work
in process
|
19,323 | 17,622 | ||||||
Finished
goods
|
9,597 | 7,679 | ||||||
$ | 68,321 | $ | 65,488 |
Six Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Balance
at beginning of period
|
$ | 9,860 | $ | 9,784 | ||||
Inventory
provision, charged to cost of sales
|
335 | 550 | ||||||
Inventory
write-offs
|
(451 | ) | (397 | ) | ||||
Balance
at end of period
|
$ | 9,744 | $ | 9,937 |
Six Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Balance
at beginning of period
|
$ | 1,928 | $ | 2,700 | ||||
Provision
for loss contracts, charged to cost of sales
|
1,454 | 1,431 | ||||||
Credit
to cost of sales upon revenue recognition
|
(1,101 | ) | (2,096 | ) | ||||
Balance
at end of period
|
$ | 2,281 | $ | 2,035 |
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Inventories
|
$ | 2,273 | $ | 953 | ||||
Accrued
expenses
|
8 | 1,082 | ||||||
$ | 2,281 | $ | 2,035 |
Weighted Average
|
April 3, 2009
|
October 3, 2008
|
||||||||||||||||||||||||||
Useful Life
(in years)
|
Cost
|
Accumulated Amortization
|
Net
|
Cost
|
Accumulated Amortization
|
Net
|
||||||||||||||||||||||
VED
Core Technology
|
50
|
$ | 30,700 | $ | (3,194 | ) | $ | 27,506 | $ | 30,700 | $ | (2,887 | ) | $ | 27,813 | |||||||||||||
VED
Application Technology
|
25
|
19,800 | (4,109 | ) | 15,691 | 19,800 | (3,713 | ) | 16,087 | |||||||||||||||||||
X-ray
Generator and Satcom
|
||||||||||||||||||||||||||||
Application
Technology
|
15 | 8,000 | (2,775 | ) | 5,225 | 8,000 | (2,508 | ) | 5,492 | |||||||||||||||||||
Antenna
and Telemetry
|
||||||||||||||||||||||||||||
Technology
|
25 | 5,300 | (347 | ) | 4,953 | 5,300 | (241 | ) | 5,059 | |||||||||||||||||||
Customer
backlog
|
1 | 580 | (580 | ) | - | 580 | (580 | ) | - | |||||||||||||||||||
Land
lease
|
46 | 11,810 | (1,308 | ) | 10,502 | 11,810 | (1,181 | ) | 10,629 | |||||||||||||||||||
Tradename
|
20
- Indefinite
|
7,600 | (165 | ) | 7,435 | 7,600 | (55 | ) | 7,545 | |||||||||||||||||||
Customer
list and programs
|
25 | 6,280 | (1,083 | ) | 5,197 | 6,280 | (950 | ) | 5,330 | |||||||||||||||||||
Noncompete
agreement
|
5 | 640 | (272 | ) | 368 | 640 | (208 | ) | 432 | |||||||||||||||||||
Patent
application fees
|
- | 147 | - | 147 | 147 | - | 147 | |||||||||||||||||||||
$ | 90,857 | $ | (13,833 | ) | $ | 77,024 | $ | 90,857 | $ | (12,323 | ) | $ | 78,534 |
Fiscal Year
|
Amount
|
|||
2009
(remaining six months)
|
$ | 1,513 | ||
2010
|
3,006 | |||
2011
|
3,006 | |||
2012
|
2,992 | |||
2013
|
2,900 | |||
Thereafter
|
60,407 | |||
$ | 73,824 |
|
Reportable Segments
|
|||||||||||||||
VED
|
Satcom
|
Other
|
Total
|
|||||||||||||
Balance
at October 3, 2008
|
$ | 132,897 | $ | 13,830 | $ | 15,884 | $ | 162,611 | ||||||||
Purchase
accounting adjustment
|
(215 | ) | (103 | ) | - | (318 | ) | |||||||||
Balance
at April 3, 2009
|
$ | 132,682 | $ | 13,727 | $ | 15,884 | $ | 162,293 |
Six Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Beginning
accrued warranty
|
$ | 4,159 | $ | 5,578 | ||||
Estimates
for product warranty, charged to cost of sales
|
2,014 | 1,406 | ||||||
Actual
costs of warranty claims
|
(2,192 | ) | (2,032 | ) | ||||
Ending
accrued warranty
|
$ | 3,981 | $ | 4,952 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Unrealized
loss on cash flow hedges, net of tax
|
$ | 4,800 | $ | 1,587 | ||||
Unrealized
actuarial loss and prior service credit
|
||||||||
for
pension liability, net of tax
|
271 | 222 | ||||||
$ | 5,071 | $ | 1,809 |
Level
1
|
Observable
inputs that reflect quoted prices (unadjusted) for identical assets or
liabilities in active markets.
|
Level
2
|
Inputs
reflect quoted prices for identical assets or liabilities in markets that
are not active; quoted prices for similar assets or liabilities in active
markets; inputs other than quoted prices that are observable for the asset
or the liability; or inputs that are derived principally from or
corroborated by observable market data by correlation or other
means.
|
Level
3
|
Unobservable
inputs reflecting the Company’s own assumptions incorporated in valuation
techniques used to determine fair value. These assumptions are required to
be consistent with market participant assumptions that are reasonably
available.
|
Fair
Value Measurements at Reporting Date Using
|
||||||||||||||||
Quoted
Prices in Active Markets for Identical Assets
|
Significant
Other Observable Inputs
|
Significant
Unobservable Inputs
|
||||||||||||||
Total
|
(Level
1)
|
(Level
2)
|
(Level
3)
|
|||||||||||||
Assets:
|
||||||||||||||||
Money
market and overnight U.S. Government securities1
|
$ | 24,766 | $ | 24,766 | $ | - | $ | - | ||||||||
Certificates
of deposit2
|
872 | - | 872 | - | ||||||||||||
Mutual
funds3
|
124 | 124 | - | - | ||||||||||||
Foreign
exchange forward derivatives4
|
182 | - | 182 | - | ||||||||||||
Total
assets at fair value
|
$ | 25,944 | $ | 24,890 | $ | 1,054 | - | |||||||||
Liabilities:
|
||||||||||||||||
Interest
rate swap derivative5
|
$ | 2,832 | $ | - | $ | 2,832 | $ | - | ||||||||
Foreign
exchange forward derivatives4
|
3,924 | - | 3,924 | - | ||||||||||||
Total
liabilities at fair value
|
$ | 6,756 | $ | - | $ | 6,756 | $ | - |
|
|
|
1
The money market and overnight U.S. Government securities are
classified as part of cash and cash equivalents in the condensed
consolidated balance
sheet.
|
||
2
The certificates of deposit are classified as part of restricted
cash in the condensed consolidated balance
sheet.
|
||
3 The
mutual funds are classified as part of other long-term assets in the
condensed consolidated balance
sheet.
|
||
4 The
foreign currency derivatives are classified as part of prepaid and other
current assets, other long-term assets and accrued expenses in the
condensed consolidated balance
sheet.
|
||
5 The
interest rate swap derivatives are classified as part of accrued expenses
and other long-term liabilities in the condensed consolidated balance
sheet.
|
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Term
loan, expiring 2014
|
$ | 84,000 | $ | 88,750 | ||||
8%
Senior subordinated notes due 2012
|
122,000 | 125,000 | ||||||
Floating
rate senior notes due
2015, net of issue discount of
$84 and $90
|
11,916 | 11,910 | ||||||
217,916 | 225,660 | |||||||
Less: Current
portion
|
- | 1,000 | ||||||
Long-term
portion
|
$ | 217,916 | $ | 224,660 | ||||
Standby
letters of credit
|
$ | 5,724 | $ | 4,609 |
Year
|
Optional
Redemption
Price
|
|||
2009
|
102 | % | ||
2010
and thereafter
|
100 | % |
Year
|
Optional
Redemption
Price
|
|||
2009
|
101 | % | ||
2010
and thereafter
|
100 | % |
Fiscal Year
|
Term
Loan
|
8% Senior
Subordinated Notes
|
Floating Rate
Senior Notes
|
Total
|
||||||||||||
2009
(remaining six months)
|
$ | - | $ | - | $ | - | $ | - | ||||||||
2010
|
- | - | - | - | ||||||||||||
2011
|
84,000 | - | - | 84,000 | ||||||||||||
2012
|
- | 122,000 | - | 122,000 | ||||||||||||
2013
|
- | - | - | - | ||||||||||||
Thereafter
|
- | - | 12,000 | 12,000 | ||||||||||||
$ | 84,000 | $ | 122,000 | $ | 12,000 | $ | 218,000 |
Asset
Derivatives
|
Liability
Derivatives
|
|||||||||
Balance
Sheet Location
|
Fair
Value
|
Balance
Sheet Location
|
Fair
Value
|
|||||||
Derivatives
designated as hedging instruments
under SFAS No. 133
|
||||||||||
Interest
rate contracts
|
Prepaid
and other current assets
|
$ | - |
Accrued
expenses
|
$ | (1,819 | ) | |||
Interest
rate contracts
|
Other
long-term assets
|
- |
Other
long-term liabilities
|
(1,013 | ) | |||||
Forward
contracts
|
Prepaid
and other current assets
|
56 |
Accrued
expenses
|
(3,924 | ) | |||||
Forward
contracts
|
Other
long-term assets
|
126 |
Other
long-term liabilities
|
- | ||||||
Total
derivatives designated as hedging instruments
under SFAS No. 133
|
$ | 182 | $ | (6,756 | ) |
Derivatives
in Statement 133
Cash
Flow Hedging Relationships
|
Amount
of
Gain
(Loss) Recognized in
OCI
on Derivative
(Effective
Portion)
|
Location
of
Gain
(Loss) Reclassified from Accumulated OCI
into Income
(Effective
Portion)
|
Amount
of
Gain
(Loss) Reclassified from Accumulated
OCI
into Income
(Effective
Portion)
|
Location
of
Gain
(Loss) Recognized in
Income
on Derivative
(Ineffective
and
Excluded
Portion)
|
Amount
of
Gain
(Loss) Recognized
in
Income
on Derivative
(Ineffective
and
Excluded
Portion )
|
||||||||||
Interest
rate contracts
|
$ | (1,587 | ) |
Interest
expense, net
|
$ | (700 | ) |
Interest
expense, net
|
$ | (28 | ) | ||||
Forward
contracts
|
(6,382 | ) |
Cost
of sales
|
(1,846 | ) |
General
and administrative
|
(225 | ) |
(a)
|
||||||
Forward
contracts
|
Research
and development
|
(114 | ) | ||||||||||||
Forward
contracts
|
Selling
and marketing
|
(63 | ) | ||||||||||||
Forward
contracts
|
General
and administrative
|
(188 | ) | ||||||||||||
Total
|
$ | (7,969 | ) | $ | (2,911 | ) | $ | (253 | ) |
|
|
Fiscal
Year
|
Operating
Leases
|
|||
2009
(remaining six months)
|
$ | 1,065 | ||
2010
|
1,756 | |||
2011
|
676 | |||
2012
|
488 | |||
2013
|
419 | |||
Thereafter
|
2,896 | |||
Total
future minimum lease payments
|
$ | 7,300 |
Fiscal
Year
|
Purchase
Contracts
|
|||
2009
(remaining six months)
|
$ | 23,785 | ||
2010
|
5,107 | |||
2011
|
233 | |||
2012
|
20 | |||
2013
|
- | |||
Total
purchase commitments
|
$ | 29,145 |
8.
|
Stock-based
Compensation Plans
|
Outstanding Options
|
Exercisable Options
|
|||||||||||||||||||||||||||||||
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
|||||||||||||||||||||||||
Balance
at October 3, 2008
|
3,349,294 | $ | 6.23 | 5.77 | $ | 24,363 | 2,556,762 | $ | 3.83 | 5.16 | $ | 23,052 | ||||||||||||||||||||
Granted
|
108,000 | 10.00 | ||||||||||||||||||||||||||||||
Exercised
|
(8,334 | ) | 4.32 | |||||||||||||||||||||||||||||
Forfeited
or cancelled
|
(6,399 | ) | 16.13 | |||||||||||||||||||||||||||||
Balance
at April 3, 2009
|
3,442,561 | $ | 6.33 | 5.40 | $ | 16,253 | 2,819,582 | $ | 4.34 | 4.82 | $ | 16,223 |
Number of Shares
|
Weighted-Average Grant-Date Fair Value Per
Share
|
|||||||
Nonvested
at October 3, 2008
|
117,154 | $ | 15.28 | |||||
Granted
|
142,721 | 8.87 | ||||||
Vested
|
(36,377 | ) | 14.81 | |||||
Forfeited
|
- | - | ||||||
Nonvested
at April 3, 2009
|
223,498 | $ | 11.26 |
Expected
term (in years)
|
6.25 | |||
Expected
volatility
|
41.20 | % | ||
Risk-free
rate
|
3.82 | % | ||
Dividend
yield
|
0 | % |
Contractual
term (in years)
|
10.00 | |||
Expected
volatility
|
51.50 | % | ||
Risk-free
rate
|
3.53 | % | ||
Dividend
yield
|
0 | % |
Expected
volatility
|
51.50 | % | ||
Risk-free
rate
|
3.54 | % | ||
Dividend
yield
|
0 | % |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
April 3,
2009
|
March 28,
2008
|
April 3,
2009
|
March 28,
2008
|
|||||||||||||
Share-based
compensation cost recognized in the income
statement by caption:
|
||||||||||||||||
Cost
of sales
|
$ | 127 | $ | 111 | $ | 244 | $ | 191 | ||||||||
Research
and development
|
45 | 38 | 87 | 69 | ||||||||||||
Selling
and marketing
|
73 | 59 | 141 | 104 | ||||||||||||
General
and administrative
|
456 | 342 | 850 | 610 | ||||||||||||
$ | 701 | $ | 550 | $ | 1,322 | $ | 974 | |||||||||
Share-based
compensation cost capitalized in inventory
|
$ | 129 | $ | 119 | $ | 253 | $ | 215 | ||||||||
Share-based
compensation cost remaining in
inventory at end of
period
|
$ | 85 | $ | 72 | $ | 85 | $ | 72 | ||||||||
Share-based
compensation expense by type of award:
|
||||||||||||||||
Stock
options
|
$ | 454 | $ | 395 | $ | 872 | $ | 732 | ||||||||
Stock
purchase plan
|
31 | 38 | 66 | 75 | ||||||||||||
Restricted
stock and units
|
216 | 117 | 384 | 167 | ||||||||||||
$ | 701 | $ | 550 | $ | 1,322 | $ | 974 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
April 3,
2009
|
March 28,
2008
|
April 3,
2009
|
March 28,
2008
|
|||||||||||||
Weighted
average common shares outstanding -- Basic
|
16,317 | 16,387 | 16,293 | 16,379 | ||||||||||||
Effect
of dilutive stock options and nonvested restricted stock awards and
units
|
1,002 | 1,269 | 1,060 | 1,365 | ||||||||||||
Weighted
average common shares outstanding -- Diluted
|
17,319 | 17,656 | 17,353 | 17,744 |
April
3,
|
March
28,
|
April
3,
|
March
28,
|
|||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Sales
to external customers
|
||||||||||||||||
VED
|
$ | 62,069 | $ | 73,744 | $ | 117,697 | $ | 137,734 | ||||||||
Satcom
equipment
|
16,174 | 17,134 | 33,625 | 34,709 | ||||||||||||
Other
|
3,660 | 3,926 | 7,727 | 8,271 | ||||||||||||
$ | 81,903 | $ | 94,804 | $ | 159,049 | $ | 180,714 | |||||||||
Intersegment
product transfers
|
||||||||||||||||
VED
|
$ | 4,422 | $ | 7,287 | $ | 9,787 | $ | 13,148 | ||||||||
Satcom
equipment
|
- | 14 | 9 | 63 | ||||||||||||
$ | 4,422 | $ | 7,301 | $ | 9,796 | $ | 13,211 | |||||||||
Capital
expenditures
|
||||||||||||||||
VED
|
$ | 629 | $ | 502 | $ | 1,494 | $ | 1,344 | ||||||||
Satcom
equipment
|
4 | 210 | 15 | 654 | ||||||||||||
Other
|
281 | 159 | 309 | 560 | ||||||||||||
$ | 914 | $ | 871 | $ | 1,818 | $ | 2,558 | |||||||||
EBITDA
|
||||||||||||||||
VED
|
$ | 11,850 | $ | 18,647 | $ | 22,201 | $ | 32,287 | ||||||||
Satcom
equipment
|
682 | 656 | 2,045 | 2,377 | ||||||||||||
Other
|
(1,779 | ) | (3,460 | ) | (3,969 | ) | (6,899 | ) | ||||||||
$ | 10,753 | $ | 15,843 | $ | 20,277 | $ | 27,765 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Total
assets
|
||||||||
VED
|
$ | 327,541 | $ | 324,483 | ||||
Satcom
equipment
|
46,615 | 48,219 | ||||||
Other
|
89,600 | 94,246 | ||||||
$ | 463,756 | $ | 466,948 |
|
•
|
EBITDA
is a component of the measures used by the Company’s board of directors
and management team to evaluate the Company’s operating
performance;
|
|
•
|
the
Senior Credit Facilities contain a covenant that requires the Company to
maintain a senior secured leverage ratio that contains EBITDA as a
component, and the Company’s management team uses EBITDA to monitor
compliance with this covenant;
|
|
•
|
EBITDA
is a component of the measures used by the Company’s management team to
make day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between the Company’s operating results and those
of competitors with different capital structures and, therefore, is a
component of the measures used by the Company’s management to facilitate
internal comparisons to competitors’ results and the Company’s industry in
general; and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by the Company of certain targets that contain EBITDA as a
component.
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
April 3,
2009
|
March 28,
2008
|
April 3,
2009
|
March 28,
2008
|
|||||||||||||
Net
income
|
$ | 3,689 | $ | 6,154 | $ | 11,344 | $ | 8,664 | ||||||||
Depreciation
and amortization
|
2,679 | 2,742 | 5,377 | 5,392 | ||||||||||||
Interest
expense, net
|
4,306 | 4,805 | 8,761 | 9,617 | ||||||||||||
Income
tax expense (benefit)
|
79 | 2,142 | (5,205 | ) | 4,092 | |||||||||||
EBITDA
|
$ | 10,753 | $ | 15,843 | $ | 20,277 | $ | 27,765 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
United
States
|
$ | 46,984 | $ | 48,593 | ||||
Canada
|
13,311 | 13,843 | ||||||
Other
|
51 | 51 | ||||||
$ | 60,346 | $ | 62,487 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
United
States
|
$ | 114,297 | $ | 114,297 | ||||
Canada
|
47,996 | 48,314 | ||||||
$ | 162,293 | $ | 162,611 |
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
April 3,
2009
|
March 28,
2008
|
April 3,
2009
|
March 28,
2008
|
|||||||||||||
United
States
|
$ | 54,495 | $ | 62,206 | $ | 103,591 | $ | 116,729 | ||||||||
All
foreign countries
|
27,408 | 32,598 | 55,458 | 63,985 | ||||||||||||
Total
sales
|
$ | 81,903 | $ | 94,804 | $ | 159,049 | $ | 180,714 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Current
assets:
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 29 | $ | 17,131 | $ | 608 | $ | 10,095 | $ | - | $ | 27,863 | ||||||||||||
Restricted
cash
|
- | - | 971 | 130 | - | 1,101 | ||||||||||||||||||
Accounts
receivable, net
|
- | 19,145 | 12,054 | 10,683 | - | 41,882 | ||||||||||||||||||
Inventories
|
- | 44,876 | 7,458 | 17,055 | (1,068 | ) | 68,321 | |||||||||||||||||
Deferred
tax assets
|
- | 12,326 | 2 | 818 | - | 13,146 | ||||||||||||||||||
Intercompany
receivable
|
- | 13,768 | 4,514 | 8,437 | (26,719 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 2,680 | 514 | 614 | - | 3,808 | ||||||||||||||||||
Total
current assets
|
29 | 109,926 | 26,121 | 47,832 | (27,787 | ) | 156,121 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 44,028 | 2,971 | 13,347 | - | 60,346 | ||||||||||||||||||
Deferred
debt issue costs, net
|
368 | 3,953 | - | - | - | 4,321 | ||||||||||||||||||
Intangible
assets, net
|
- | 55,795 | 13,864 | 7,365 | - | 77,024 | ||||||||||||||||||
Goodwill
|
- | 93,375 | 20,973 | 47,945 | - | 162,293 | ||||||||||||||||||
Other
long-term assets
|
- | 3,271 | 293 | 87 | - | 3,651 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
192,348 | 107,451 | - | - | (299,799 | ) | - | |||||||||||||||||
Total
assets
|
$ | 192,745 | $ | 418,834 | $ | 64,222 | $ | 116,576 | $ | (328,621 | ) | $ | 463,756 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
liabilities:
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | - | $ | - | $ | - | $ | - | $ | - | ||||||||||||
Accounts
payable
|
- | 11,944 | 2,442 | 6,679 | - | 21,065 | ||||||||||||||||||
Accrued
expenses
|
155 | 17,277 | 1,497 | 2,995 | - | 21,924 | ||||||||||||||||||
Product
warranty
|
- | 1,913 | 527 | 1,541 | - | 3,981 | ||||||||||||||||||
Income
taxes payable
|
- | 1 | 101 | 3,510 | - | 3,612 | ||||||||||||||||||
Advance
payments from customers
|
- | 7,318 | 3,346 | 2,234 | - | 12,898 | ||||||||||||||||||
Intercompany
payable
|
26,719 | - | - | - | (26,719 | ) | - | |||||||||||||||||
Total
current liabilities
|
26,874 | 38,453 | 7,913 | 16,959 | (26,719 | ) | 63,480 | |||||||||||||||||
Deferred
income taxes
|
- | 21,661 | - | 4,847 | - | 26,508 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
11,916 | 206,000 | - | - | - | 217,916 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,449 | - | 448 | - | 1,897 | ||||||||||||||||||
Total
liabilities
|
38,790 | 267,563 | 7,913 | 23,289 | (27,754 | ) | 309,801 | |||||||||||||||||
Common
stock
|
167 | - | - | - | - | 167 | ||||||||||||||||||
Parent
investment
|
- | 51,089 | 43,167 | 58,351 | (152,607 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
73,824 | - | - | - | - | 73,824 | ||||||||||||||||||
Accumulated
other comprehensive loss
|
(5,071 | ) | (5,071 | ) | - | (1,110 | ) | 6,181 | (5,071 | ) | ||||||||||||||
Retained
earnings
|
87,835 | 105,253 | 13,142 | 36,046 | (154,441 | ) | 87,835 | |||||||||||||||||
Treasury
stock, at cost
|
(2,800 | ) | - | - | - | - | (2,800 | ) | ||||||||||||||||
Total
stockholders’ equity
|
153,955 | 151,271 | 56,309 | 93,287 | (300,867 | ) | 153,955 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 192,745 | $ | 418,834 | $ | 64,222 | $ | 116,576 | $ | (328,621 | ) | $ | 463,756 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Current
assets:
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 84 | $ | 26,272 | $ | 493 | $ | 1,821 | $ | - | $ | 28,670 | ||||||||||||
Restricted
cash
|
- | - | 629 | 147 | - | 776 | ||||||||||||||||||
Accounts
receivable, net
|
- | 22,453 | 12,353 | 12,542 | - | 47,348 | ||||||||||||||||||
Inventories
|
- | 42,066 | 6,759 | 17,653 | (990 | ) | 65,488 | |||||||||||||||||
Deferred
tax assets
|
- | 10,853 | 2 | 556 | - | 11,411 | ||||||||||||||||||
Intercompany
receivable
|
- | 8,523 | 5,135 | 13,454 | (27,112 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 2,370 | 632 | 821 | - | 3,823 | ||||||||||||||||||
Total
current assets
|
84 | 112,537 | 26,003 | 46,994 | (28,102 | ) | 157,516 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 45,556 | 3,047 | 13,884 | - | 62,487 | ||||||||||||||||||
Deferred
debt issue costs, net
|
392 | 4,602 | - | - | - | 4,994 | ||||||||||||||||||
Intangible
assets, net
|
- | 56,700 | 14,168 | 7,666 | - | 78,534 | ||||||||||||||||||
Goodwill
|
- | 93,375 | 20,973 | 48,263 | - | 162,611 | ||||||||||||||||||
Other
long-term assets
|
- | 383 | 287 | 136 | - | 806 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
182,869 | 101,193 | - | - | (284,062 | ) | - | |||||||||||||||||
Total
assets
|
$ | 183,345 | $ | 415,381 | $ | 64,478 | $ | 116,943 | $ | (313,199 | ) | $ | 466,948 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
liabilities:
|
||||||||||||||||||||||||
Current
portion of long-term debt
|
$ | - | $ | 1,000 | $ | - | $ | - | $ | - | $ | 1,000 | ||||||||||||
Accounts
payable
|
272 | 10,893 | 2,116 | 7,828 | - | 21,109 | ||||||||||||||||||
Accrued
expenses
|
186 | 14,905 | 3,143 | 4,810 | - | 23,044 | ||||||||||||||||||
Product
warranty
|
- | 2,002 | 538 | 1,619 | - | 4,159 | ||||||||||||||||||
Income
taxes payable
|
- | 1,280 | 213 | 6,273 | - | 7,766 | ||||||||||||||||||
Advance
payments from customers
|
- | 7,624 | 3,132 | 1,579 | - | 12,335 | ||||||||||||||||||
Intercompany
payable
|
27,112 | - | - | - | (27,112 | ) | - | |||||||||||||||||
Total
current liabilities
|
27,570 | 37,704 | 9,142 | 22,109 | (27,112 | ) | 69,413 | |||||||||||||||||
Deferred
income taxes
|
- | 21,922 | - | 5,399 | - | 27,321 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
11,910 | 212,750 | - | - | - | 224,660 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,213 | - | 476 | - | 1,689 | ||||||||||||||||||
Total
liabilities
|
39,480 | 273,589 | 9,142 | 29,019 | (28,147 | ) | 323,083 | |||||||||||||||||
Common
stock
|
165 | - | - | - | - | 165 | ||||||||||||||||||
Parent
investment
|
- | 50,020 | 43,167 | 58,114 | (151,301 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
71,818 | - | - | - | - | 71,818 | ||||||||||||||||||
Accumulated
other comprehensive loss
|
(1,809 | ) | (1,809 | ) | - | (283 | ) | 2,092 | (1,809 | ) | ||||||||||||||
Retained
earnings
|
76,491 | 93,581 | 12,169 | 30,093 | (135,843 | ) | 76,491 | |||||||||||||||||
Treasury
stock, at cost
|
(2,800 | ) | - | - | - | - | (2,800 | ) | ||||||||||||||||
Total
stockholders’ equity
|
143,865 | 141,792 | 55,336 | 87,924 | (285,052 | ) | 143,865 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 183,345 | $ | 415,381 | $ | 64,478 | $ | 116,943 | $ | (313,199 | ) | $ | 466,948 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 52,641 | $ | 17,077 | $ | 30,510 | $ | (18,325 | ) | $ | 81,903 | |||||||||||
Cost
of sales
|
- | 39,798 | 14,124 | 24,538 | (18,323 | ) | 60,137 | |||||||||||||||||
Gross
profit
|
- | 12,843 | 2,953 | 5,972 | (2 | ) | 21,766 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 1,074 | 3 | 2,080 | - | 3,157 | ||||||||||||||||||
Selling
and marketing
|
- | 1,820 | 988 | 1,993 | - | 4,801 | ||||||||||||||||||
General
and administrative
|
- | 4,180 | 1,131 | (115 | ) | - | 5,196 | |||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 390 | 151 | 150 | - | 691 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 41 | - | 3 | - | 44 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 7,505 | 2,273 | 4,111 | - | 13,889 | ||||||||||||||||||
Operating
income
|
- | 5,338 | 680 | 1,861 | (2 | ) | 7,877 | |||||||||||||||||
Interest
expense (income), net
|
253 | 4,045 | (3 | ) | 11 | - | 4,306 | |||||||||||||||||
Gain
on debt extinguishment
|
- | (197 | ) | - | - | - | (197 | ) | ||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(253 | ) | 1,490 | 683 | 1,850 | (2 | ) | 3,768 | ||||||||||||||||
Income
tax (benefit) expense
|
(98 | ) | (251 | ) | 271 | 157 | - | 79 | ||||||||||||||||
Equity
in income of subsidiaries
|
3,844 | 2,103 | - | - | (5,947 | ) | - | |||||||||||||||||
Net
income
|
$ | 3,689 | $ | 3,844 | $ | 412 | $ | 1,693 | $ | (5,949 | ) | $ | 3,689 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 60,336 | $ | 21,125 | $ | 34,490 | $ | (21,147 | ) | $ | 94,804 | |||||||||||
Cost
of sales
|
- | 42,877 | 17,891 | 27,079 | (21,109 | ) | 66,738 | |||||||||||||||||
Gross
profit
|
- | 17,459 | 3,234 | 7,411 | (38 | ) | 28,066 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 729 | 272 | 1,929 | - | 2,930 | ||||||||||||||||||
Selling
and marketing
|
- | 2,070 | 1,175 | 2,083 | - | 5,328 | ||||||||||||||||||
General
and administrative
|
- | 3,817 | 1,018 | 657 | - | 5,492 | ||||||||||||||||||
Amortization
of acquisition-related intangible
assets
|
- | 100 | 531 | 150 | - | 781 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 22 | 10 | 9 | - | 41 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 6,738 | 3,006 | 4,828 | - | 14,572 | ||||||||||||||||||
Operating
income
|
- | 10,721 | 228 | 2,583 | (38 | ) | 13,494 | |||||||||||||||||
Interest
expense (income), net
|
512 | 4,314 | (17 | ) | (4 | ) | - | 4,805 | ||||||||||||||||
Loss
on debt extinguishment
|
393 | - | - | - | - | 393 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(905 | ) | 6,407 | 245 | 2,587 | (38 | ) | 8,296 | ||||||||||||||||
Income
tax (benefit) expense
|
(344 | ) | 2,741 | (135 | ) | (120 | ) | - | 2,142 | |||||||||||||||
Equity
in income of subsidiaries
|
6,715 | 3,049 | - | - | (9,764 | ) | - | |||||||||||||||||
Net
income
|
$ | 6,154 | $ | 6,715 | $ | 380 | $ | 2,707 | $ | (9,802 | ) | $ | 6,154 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 98,856 | $ | 36,784 | $ | 62,233 | $ | (38,824 | ) | $ | 159,049 | |||||||||||
Cost
of sales
|
- | 76,065 | 30,737 | 49,311 | (38,746 | ) | 117,367 | |||||||||||||||||
Gross
profit
|
- | 22,791 | 6,047 | 12,922 | (78 | ) | 41,682 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 1,758 | 3 | 3,579 | - | 5,340 | ||||||||||||||||||
Selling
and marketing
|
- | 3,562 | 2,235 | 3,993 | - | 9,790 | ||||||||||||||||||
General
and administrative
|
- | 7,894 | 2,154 | 352 | - | 10,400 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 780 | 304 | 301 | - | 1,385 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 57 | - | 7 | - | 64 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 14,051 | 4,696 | 8,232 | - | 26,979 | ||||||||||||||||||
Operating
income
|
- | 8,740 | 1,351 | 4,690 | (78 | ) | 14,703 | |||||||||||||||||
Interest
expense (income), net
|
531 | 8,198 | (8 | ) | 40 | - | 8,761 | |||||||||||||||||
Gain
on debt extinguishment
|
- | (197 | ) | - | - | - | (197 | ) | ||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(531 | ) | 739 | 1,359 | 4,650 | (78 | ) | 6,139 | ||||||||||||||||
Income
tax (benefit) expense
|
(203 | ) | (4,085 | ) | 386 | (1,303 | ) | - | (5,205 | ) | ||||||||||||||
Equity
in income of subsidiaries
|
11,672 | 6,848 | - | - | (18,520 | ) | - | |||||||||||||||||
Net
income
|
$ | 11,344 | $ | 11,672 | $ | 973 | $ | 5,953 | $ | (18,598 | ) | $ | 11,344 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 110,098 | $ | 40,951 | $ | 69,328 | $ | (39,663 | ) | $ | 180,714 | |||||||||||
Cost
of sales
|
- | 80,308 | 34,476 | 53,306 | (39,578 | ) | 128,512 | |||||||||||||||||
Gross
profit
|
- | 29,790 | 6,475 | 16,022 | (85 | ) | 52,202 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 1,621 | 421 | 3,612 | - | 5,654 | ||||||||||||||||||
Selling
and marketing
|
- | 3,993 | 2,187 | 4,320 | - | 10,500 | ||||||||||||||||||
General
and administrative
|
- | 7,535 | 2,088 | 2,022 | - | 11,645 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 668 | 593 | 301 | - | 1,562 | ||||||||||||||||||
Net
loss on disposition of assets
|
- | 44 | 12 | 19 | - | 75 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 13,861 | 5,301 | 10,274 | - | 29,436 | ||||||||||||||||||
Operating
income
|
- | 15,929 | 1,174 | 5,748 | (85 | ) | 22,766 | |||||||||||||||||
Interest
expense (income), net
|
1,057 | 8,599 | (37 | ) | (2 | ) | - | 9,617 | ||||||||||||||||
Loss
on debt extinguishment
|
393 | - | - | - | - | 393 | ||||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(1,450 | ) | 7,330 | 1,211 | 5,750 | (85 | ) | 12,756 | ||||||||||||||||
Income
tax (benefit) expense
|
(551 | ) | 3,482 | 119 | 1,042 | - | 4,092 | |||||||||||||||||
Equity
in income of subsidiaries
|
9,563 | 5,715 | - | - | (15,278 | ) | - | |||||||||||||||||
Net
income
|
$ | 8,664 | $ | 9,563 | $ | 1,092 | $ | 4,708 | $ | (15,363 | ) | $ | 8,664 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (1,092 | ) | $ | 8,429 | $ | 227 | $ | 301 | $ | - | $ | 7,865 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (1,679 | ) | (112 | ) | (27 | ) | - | (1,818 | ) | ||||||||||||||
Net
cash used in investing activities
|
- | (1,679 | ) | (112 | ) | (27 | ) | - | (1,818 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
- | (7,495 | ) | - | - | - | (7,495 | ) | ||||||||||||||||
Proceeds
from issuance of common stock to employees
|
605 | - | - | - | - | 605 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
36 | - | - | - | - | 36 | ||||||||||||||||||
Intercompany
dividends
|
396 | (8,396 | ) | - | 8,000 | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
1,037 | (15,891 | ) | - | 8,000 | - | (6,854 | ) | ||||||||||||||||
Net
(decrease) increase in cash and cash equivalents
|
(55 | ) | (9,141 | ) | 115 | 8,274 | - | (807 | ) | |||||||||||||||
Cash
and cash equivalents at beginning of period
|
84 | 26,272 | 493 | 1,821 | - | 28,670 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 29 | $ | 17,131 | $ | 608 | $ | 10,095 | $ | - | $ | 27,863 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (1,812 | ) | $ | 1,779 | $ | 8,749 | $ | 1,723 | $ | - | $ | 10,439 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (1,941 | ) | (95 | ) | (522 | ) | - | (2,558 | ) | ||||||||||||||
Proceeds
from adjustment to acquisition purchase price
|
- | 1,615 | - | - | - | 1,615 | ||||||||||||||||||
Payment
of patent application fees
|
- | - | (147 | ) | - | - | (147 | ) | ||||||||||||||||
Net
cash used in investing activities
|
- | (326 | ) | (242 | ) | (522 | ) | - | (1,090 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
(6,000 | ) | (4,000 | ) | - | - | - | (10,000 | ) | |||||||||||||||
Proceeds
from issuance of common stock to employees
|
418 | - | - | - | - | 418 | ||||||||||||||||||
Intercompany
dividends
|
6,200 | (6,200 | ) | - | - | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
618 | (10,200 | ) | - | - | - | (9,582 | ) | ||||||||||||||||
Net
(decrease) increase in cash and cash equivalents
|
(1,194 | ) | (8,747 | ) | 8,507 | 1,201 | - | (233 | ) | |||||||||||||||
Cash
and cash equivalents at beginning of period
|
1,378 | 16,518 | 958 | 1,620 | - | 20,474 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 184 | $ | 7,771 | $ | 9,465 | $ | 2,821 | $ | - | $ | 20,241 |
Six
Months Ended
|
||||||||||||||||||||||||
April
3, 2009
|
March
28, 2008
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Orders
|
Amount
|
Orders
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 75.6 | 41 | % | $ | 66.7 | 36 | % | $ | 8.9 | 13 | % | ||||||||||||
Medical
|
39.7 | 22 | 36.7 | 20 | 3.0 | 8 | ||||||||||||||||||
Communications
|
54.8 | 30 | 59.9 | 32 | (5.1 | ) | (9 | ) | ||||||||||||||||
Industrial
|
11.1 | 6 | 14.3 | 8 | (3.2 | ) | (22 | ) | ||||||||||||||||
Scientific
|
1.3 | 1 | 7.6 | 4 | (6.3 | ) | (83 | ) | ||||||||||||||||
Total
|
$ | 182.5 | 100 | % | $ | 185.2 | 100 | % | $ | (2.7 | ) | (1 |
)%
|
·
|
Radar and Electronic
Warfare: The majority of our orders in the radar and
electronic warfare markets are products for domestic and international
defense and government end uses. Orders in these markets are characterized
by many smaller orders in the $0.5 million to $3.0 million range by
product or program, and the timing of the receipt of these orders may vary
from year to year. On a combined basis, orders for the radar and
electronic warfare markets increased approximately 13% from an aggregate
of $66.7 million in the first six months of fiscal year 2008 to an
aggregate of $75.6 million in the first six months of fiscal year 2009.
The increase in orders for these combined markets resulted primarily from
the timing of the placement of orders to support various foreign and
domestic radar programs, as well as the receipt of several large
development orders to support various radar programs, and was partially
offset by delays in the receipt of orders for certain other defense
programs.
|
·
|
Medical: Orders for
our medical products consist of orders for medical imaging applications,
such as x-ray imaging, magnetic resonance imaging (“MRI”), and positron
emission tomography (“PET”) applications, and for radiation therapy
applications for the treatment of cancer. The 8% increase in medical
orders was due to increased demand for products to support radiation
therapy applications. This increase was partially offset by a decrease in
demand for products to support x-ray imaging applications due to the
weakening of global economies.
|
·
|
Communications: The
9% decrease in communications orders was primarily attributable to
decreases in orders to support commercial communications applications,
including direct-to-home broadcast, fixed satellite broadcast and
satellite news gathering applications, as well as commercial radio
broadcast applications. We believe that these decreases were largely due
to the weakening of global economies. Delays in the timing of orders
received by our Malibu division also contributed to the decrease in
communications orders; we expect to receive a number of the Malibu
division’s delayed orders later in fiscal year 2009. These decreases were
partially offset by an increase in orders for military communications
programs, including an approximately $13 million order for the Warfighter
Information Network – Tactical (WIN-T) program. Military communications is
a relatively new sector of the overall communications market for us. We
expect our participation in military communications programs to continue
to grow.
|
·
|
Industrial: Orders in
the industrial market are cyclical and are generally tied to the state of
the economy. The $3.2 million decrease in industrial orders was primarily
attributable to decreases in orders for products used in industrial
fabrication applications, including semiconductor wafer fabrication, and
industrial heating applications.
|
·
|
Scientific: Orders in
the scientific market are historically one-time projects and can fluctuate
significantly from period to period. The $6.3 million decrease in
scientific orders was primarily the result of the receipt of a $5.6
million order in the first six months of fiscal year 2008 for products to
support a new accelerator project for fusion research at an international
scientific institute. This order was not expected to, and did not, repeat
in the first six months of fiscal year 2009; shipments for this order are
scheduled to be completed in fiscal year
2011.
|
Three
Months Ended
|
Increase
|
||||||||||||||||||||
April
3, 2009
|
March
28, 2008
|
(Decrease)
|
|||||||||||||||||||
%
of
|
%
of
|
||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
|||||||||||||||||
Sales
|
$ | 81.9 | 100.0 | % | $ | 94.8 | 100.0 | % | $ | (12.9 | ) | ||||||||||
Cost
of sales
|
60.1 | 73.4 | 66.7 | 70.4 | (6.6 | ) | |||||||||||||||
Gross
profit
|
21.8 | 26.6 | 28.1 | 29.6 | (6.3 | ) | |||||||||||||||
Research
and development
|
3.2 | 3.9 | 2.9 | 3.1 | 0.3 | ||||||||||||||||
Selling
and marketing
|
4.8 | 5.9 | 5.3 | 5.6 | (0.5 | ) | |||||||||||||||
General
and administrative
|
5.2 | 6.3 | 5.5 | 5.8 | (0.3 | ) | |||||||||||||||
Amortization
of acquisition-related
intangibles
|
0.7 | 0.9 | 0.8 | 0.8 | (0.1 |
)
|
|||||||||||||||
Net
loss on disposition of assets
|
- | - | - | - | - | ||||||||||||||||
Operating
income
|
7.9 | 9.6 | 13.5 | 14.2 | (5.6 | ) | |||||||||||||||
Interest
expense, net
|
4.3 | 5.3 | 4.8 | 5.1 | (0.5 | ) | |||||||||||||||
(Gain)
loss on debt extinguishment
|
(0.2 | ) | (0.2 | ) | 0.4 | 0.4 | (0.6 | ) | |||||||||||||
Income
before taxes
|
3.8 | 4.6 | 8.3 | 8.8 | (4.5 | ) | |||||||||||||||
Income
tax expense
|
0.1 | 0.1 | 2.1 | 2.2 | (2.0 | ) | |||||||||||||||
Net
income
|
$ | 3.7 | 4.5 | % | $ | 6.2 | 6.5 | % | $ | (2.5 | ) | ||||||||||
Other
Data:
|
|||||||||||||||||||||
EBITDA
(a)
|
$ | 10.8 | 13.2 | % | $ | 15.8 | 16.7 | % | $ | (5.0 | ) | ||||||||||
|
|
Note: Totals
may not equal the sum of the component line items due to independent
rounding. Percentages are calculated based on rounded dollar amounts
presented.
|
(a)
|
EBITDA
is the measure used by the CODM to evaluate segment profit or loss. EBITDA
represents earnings before net interest expense, provision for income
taxes and depreciation and amortization. We believe that EBITDA is a more
meaningful representation of operating performance for leveraged
businesses like our own and, therefore, use this metric as our primary
measure of profitability. For the reasons listed below, we believe EBITDA
provides investors better understanding of our financial performance in
connection with their analysis of our
business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain a covenant that requires us to maintain a
senior secured leverage ratio that contains EBITDA as a component, and our
management team uses EBITDA to monitor compliance with this
covenant;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for, net income, cash flows from
operating activities or other statements of operations or statements of
cash flows data prepared in accordance with
GAAP.
|
|
For
a reconciliation of Net Income to EBITDA, see Note 11 of the
accompanying unaudited condensed consolidated financial
statements.
|
Three
Months Ended
|
||||||||||||||||||||||||
April
3, 2009
|
March
28, 2008
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 34.3 | 42 | % | $ | 39.7 | 42 | % | $ | (5.4 | ) | (14 | ) % | |||||||||||
Medical
|
15.6 | 19 | 17.0 | 18 | (1.4 | ) | (8 | ) | ||||||||||||||||
Communications
|
25.3 | 31 | 28.5 | 30 | (3.2 | ) | (11 | ) | ||||||||||||||||
Industrial
|
4.4 | 5 | 6.6 | 7 | (2.2 | ) | (33 | ) | ||||||||||||||||
Scientific
|
2.3 | 3 | 3.0 | 3 | (0.7 | ) | (23 | ) | ||||||||||||||||
Total
|
$ | 81.9 | 100 | % | $ | 94.8 | 100 | % | $ | (12.9 | ) | (14 | ) % |
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are products for domestic and international defense and
government end uses. The timing of the receipt of orders and subsequent
shipments in these markets may vary from year to year. On a combined
basis, sales for these two markets decreased approximately 14% from $39.7
million in the three months ended March 28, 2008 to $34.3 million in the
three months ended April 3, 2009, primarily due to an expected $1.9
million decrease in shipments of products to support the Aegis weapons
system and decreases in sales for several other radar programs due to the
timing of order receipts for those
programs.
|
Demand for our products to support ships with the Aegis weapons system has two components: we support new ship builds and we provide spare and repair products for previously fielded ships. Over the past several years, we have seen high demand for products to support a significant number of funded new ship builds for the Aegis weapons program for U.S. and international military customers. We have now completed supplying our products required to support these funded new ship builds, and, as a result, we expect the near-term demand to be primarily for spare and repair products and the near-term sales to be roughly half of the approximately $20 million fiscal year 2008 sales level. We expect demand for our products to increase again in several years as the new ships are commissioned, deployed and added to the installed base, after which they also will require spare and repair products. |
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, MRI and PET applications, and for radiation therapy
applications for the treatment of cancer. The 8% decrease in medical
product sales was due to decreased sales of x-ray imaging products to
international customers as a result of the weakening of global
economies.
|
·
|
Communications: The
11% decrease in sales in the communications market was primarily
attributable to decreases in sales to support certain commercial
communications applications, including satellite news gathering and
direct-to-home broadcast applications as well as commercial radio
broadcast applications. We believe the decreases were largely due to the
weakening of global economies. These decreases were partially offset by an
increase in sales of products for military communications programs, which
is a relatively new sector of the overall communications market for us. We
expect our participation in military communications programs to continue
to grow.
|
·
|
Industrial: Sales in the
industrial market are cyclical and are generally tied to the state of the
economy. The $2.2 million decrease in sales of industrial products was
primarily attributable to decreases in orders for products used in
industrial fabrication applications, including semiconductor wafer
fabrication, and industrial heating
applications.
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $0.7 million decrease
in scientific sales was primarily the result of the recent completion of
product shipments for the Spallation Neutron Source at Oakridge National
Laboratory and the timing of certain other scientific
programs.
|
Three Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Company
sponsored
|
$ | 3.2 | $ | 2.9 | ||||
Customer
sponsored, charged to cost of sales
|
4.1 | 3.5 | ||||||
$ | 7.3 | $ | 6.4 |
Six
Months Ended
|
Increase
|
||||||||||||||||||||
April
3, 2009
|
March
28, 2008
|
(Decrease)
|
|||||||||||||||||||
%
of
|
%
of
|
||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
|||||||||||||||||
Sales
|
$ | 159.0 | 100.0 | % | $ | 180.7 | 100.0 | % | $ | (21.7 | ) | ||||||||||
Cost
of sales
|
117.4 | 73.8 | 128.5 | 71.1 | (11.1 | ) | |||||||||||||||
Gross
profit
|
41.7 | 26.2 | 52.2 | 28.9 | (10.5 | ) | |||||||||||||||
Research
and development
|
5.3 | 3.3 | 5.7 | 3.2 | (0.4 | ) | |||||||||||||||
Selling
and marketing
|
9.8 | 6.2 | 10.5 | 5.8 | (0.7 | ) | |||||||||||||||
General
and administrative
|
10.4 | 6.5 | 11.6 | 6.4 | (1.2 | ) | |||||||||||||||
Amortization
of acquisition-related
intangibles
|
1.4 | 0.9 | 1.6 | 0.9 | (0.2 | ) | |||||||||||||||
Net
loss on disposition of assets
|
0.1 | 0.1 | 0.1 | 0.1 | - | ||||||||||||||||
Operating
income
|
14.7 | 9.2 | 22.8 | 12.6 | (8.1 | ) | |||||||||||||||
Interest
expense, net
|
8.8 | 5.5 | 9.6 | 5.3 | (0.8 | ) | |||||||||||||||
(Gain)
loss on debt extinguishment
|
(0.2 | ) | (0.1 | ) | 0.4 | 0.2 | (0.6 | ) | |||||||||||||
Income
before taxes
|
6.1 | 3.8 | 12.8 | 7.1 | (6.7 | ) | |||||||||||||||
Income
tax (benefit) expense
|
(5.2 | ) | (3.3 | ) | 4.1 | 2.3 | (9.3 | ) | |||||||||||||
Net
income
|
$ | 11.3 | 7.1 | % | $ | 8.7 | 4.8 | % | $ | 2.6 | |||||||||||
Other
Data:
|
|||||||||||||||||||||
EBITDA
(a)
|
$ | 20.3 | 12.8 | % | $ | 27.8 | 15.4 | % | $ | (7.5 | ) | ||||||||||
|
|
|
|||||||||||||||||||
Note: Totals
may not equal the sum of the component line items due to independent
rounding. Percentages are calculated based on rounded dollar amounts
presented.
|
(a)
|
EBITDA
is the measure used by the CODM to evaluate segment profit or loss. EBITDA
represents earnings before net interest expense, provision for income
taxes and depreciation and amortization. We believe that EBITDA is a more
meaningful representation of operating performance for leveraged
businesses like our own and, therefore, use this metric as our primary
measure of profitability. For the reasons listed below, we believe EBITDA
provides investors better understanding of our financial performance in
connection with their analysis of our
business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain a covenant that requires us to maintain a
senior secured leverage ratio that contains EBITDA as a component, and our
management team uses EBITDA to monitor compliance with this
covenant;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and therefore is a component
of the measures used by the management to facilitate internal comparisons
to competitors' results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for, net income, cash flows from
operating activities or other statements of operations or statements of
cash flows data prepared in accordance with
GAAP.
|
For a
reconciliation of EBITDA to Net Income,
see Note 11 of
the accompanying
unaudited condensed consolidated financial
statements.
|
Six
Months Ended
|
||||||||||||||||||||||||
April
3, 2009
|
March
28, 2008
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 62.3 | 39 | % | $ | 73.5 | 41 | % | $ | (11.2 | ) | (15 | ) % | |||||||||||
Medical
|
31.4 | 20 | 32.7 | 18 | (1.3 | ) | (4 | ) | ||||||||||||||||
Communications
|
51.5 | 32 | 56.8 | 31 | (5.3 | ) | (9 | ) | ||||||||||||||||
Industrial
|
9.8 | 6 | 12.1 | 7 | (2.3 | ) | (19 | ) | ||||||||||||||||
Scientific
|
4.0 | 3 | 5.6 | 3 | (1.6 | ) | (29 | ) | ||||||||||||||||
Total
|
$ | 159.0 | 100 | % | $ | 180.7 | 100 | % | $ | (21.7 | ) | (12 | ) % |
·
|
Radar and Electronic
Warfare: The majority of our sales in the radar and electronic
warfare markets are for products for domestic and international defense
and government end uses. The timing of the receipt of orders and
subsequent shipments in these markets may vary from year to year. On a
combined basis, sales for these two markets decreased approximately 15%
from $73.5 million in the six months ended March 28, 2008 to $62.3 million
in the six months ended April 3, 2009. The decrease in sales was due
primarily to an expected $3.9 million decrease in shipments of products to
support the Aegis weapons system and decreases in sales for several other
radar and electronic warfare programs due to the timing of order receipts
for those programs.
|
Demand for our products to support ships with the Aegis weapons system has two components: we support new ship builds and we provide spare and repair products for previously fielded ships. Over the past several years, we have seen high demand for products to support a significant number of funded new ship builds for the Aegis weapons program for U.S. and international military customers. We have now completed supplying our products required to support these funded new ship builds, and, as a result, we expect the near-term demand to be primarily for spare and repair products and the near-term sales to be roughly half of the approximately $20 million fiscal year 2008 sales level. We expect demand for our products to increase again in several years as the new ships are commissioned, deployed and added to the installed base, after which they also will require spare and repair products. |
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, MRI and PET applications, and for radiation therapy
applications for the treatment of cancer. The 4% decrease in sales of our
medical products was primarily due to decreased sales of x-ray imaging
products to international customers as a result of the weakening of global
economies. This decrease was partially offset by increased demand for
products to support radiation therapy
applications.
|
·
|
Communications: The
9% decrease in sales in the communications market was primarily
attributable to decreases in sales to support certain commercial
communications applications, including direct-to-home broadcast, fixed
satellite broadcast and satellite news gathering applications as well as
commercial radio broadcast applications. We believe the decreases were
largely due to the weakening of global economies. These decreases were
partially offset by an increase in sales of products for military
communications programs, which is a relatively new sector of the overall
communications market for us. We expect our participation in military
communications programs to continue to
grow.
|
·
|
Industrial: Sales in the
industrial market are cyclical and are generally tied to the state of the
economy. The $2.3 million decrease in industrial sales was due to
decreases in demand for products used in industrial fabrication
applications, including semiconductor wafer fabrication, and a wide
variety of other industrial
applications.
|
·
|
Scientific: Sales
in the scientific market are historically one-time projects and can
fluctuate significantly from period to period. The $1.6 million decrease
in scientific sales was primarily the result of the recent completion of
product shipments for the Spallation Neutron Source at Oakridge National
Laboratory and the timing of certain other scientific
programs.
|
Six Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Company
sponsored
|
$ | 5.3 | $ | 5.7 | ||||
Customer
sponsored, charged to cost of sales
|
7.3 | 7.2 | ||||||
$ | 12.6 | $ | 12.9 |
April
3,
|
October
3,
|
|||||||
2009
|
2008
|
|||||||
Cash
and cash equivalents
|
$ | 27.9 | $ | 28.7 | ||||
Working
capital
|
$ | 92.6 | $ | 88.1 |
Six
Months Ended
|
||||||||
April
3,
|
March
28,
|
|||||||
2009
|
2008
|
|||||||
Net
cash provided by operating activities
|
$ | 7.9 | $ | 10.4 | ||||
Net
cash used in investing activities
|
(1.8 | ) | (1.1 | ) | ||||
Net
cash used in financing activities
|
(6.9 | ) | (9.5 | ) | ||||
Net
decrease in cash and cash equivalents
|
$ | (0.8 | ) | $ | (0.2 | ) |
Nominee
|
For Votes
|
Withheld Votes
|
||||||
O.
Joe Caldarelli
|
14,918,464 | 869,070 | ||||||
Michael
F. Finley
|
14,487,532 | 1,730,934 |
Votes
|
Shares
|
|||
For
|
11,037,657 | |||
Against
|
4,356,422 | |||
Abstain
|
1,945 |
Votes
|
Shares
|
|||
For
|
12,082,110 | |||
Against
|
3,311,347 | |||
Abstain
|
2,567 |
Votes
|
Shares
|
|||
For
|
15,701,112 | |||
Against
|
81,157 | |||
Abstain
|
4,665 |
No.
|
Description
|
||
31.1 |
Certification
of Chief Executive Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
||
31.2 |
Certification
of Chief Financial Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
||
32.1 |
Certifications
of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
||
32.2 |
Certifications
of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
Dated:
May 13, 2009
|
/s/ JOEL A. LITTMAN |
|
Joel
A. Littman
Chief
Financial Officer, Treasurer and Secretary
(Duly
Authorized Officer and Chief Financial
Officer)
|